Pharmaceuticals
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
* 250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far * Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 * Completion of rec...
2026-07-17 11:48
5016
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. * The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix...
2026-07-17 06:00
3464
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. * Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research...
2026-07-16 08:30
3853
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. * OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently com...
2026-07-16 04:30
3143
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...
2026-07-16 00:12
6115
Seegene: "Virus-Only Testing May Miss Pneumonia-associated Bacterial Respiratory Pathogens" Calls for a Shift to Comprehensive Syndromic PCR Testing
* Virus-only testing may miss pneumonia-associated bacterial co-detections in 78% of virus-positive cases, while bacteria-only testing may miss viral co-detections in 88% of cases positive for pneumonia-associated bacterial pathogens * Global Million Clinical Study (GMCS) to build clinical ev...
2026-07-15 21:00
5501
Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board
Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and respiratory medicine to guide its immunology and inflammatio...
2026-07-15 21:00
4995
Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies — — First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); demonstrated mean reductions of...
2026-07-15 20:47
3615
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc.
2026-07-15 19:00
2185
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, and Kelun-Biotech (6990.HK) tod...
2026-07-15 18:01
2793
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and GCGR. - ASC48 demonstra...
2026-07-15 18:00
2636
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced thatthe National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (...
2026-07-15 18:00
2418
LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio
Executive Chair Mark Crotty to continue guiding long-term strategic direction
PERTH, Australia, July 15, 2026 /PRNewswire/ -- LumaCina,
2026-07-15 09:47
4022
GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
TAIPEI and SAN DIEGO, July 14, 2026 /PRNewswire/ -- GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed up to NT$500 million (approximately US$15.5 ...
2026-07-15 09:09
3435
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...
2026-07-15 08:00
3034
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-s...
2026-07-15 08:00
2971
Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the ...
2026-07-15 08:00
3160
ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process
NEWARK, Del., July 14, 2026 /PRNewswire/ -- Recently, ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for its GMP-grade Human IL-15 pr...
2026-07-15 00:00
3858
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
* BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 proof-of-concept trial for cardiovascular risk reduction. * The QUELL-CV trial is designe...
2026-07-14 21:30
3965
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the pe...
2026-07-14 16:18
2673
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 308 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 294 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
13117
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
2026-07-15 12:00
10064
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
9021